SuperworthCingulate CING
- Market cap
- $72.4M
- PE
- n/m
- a loss over the last year
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- n/m
- not a meaningful number
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- n/m
- not a meaningful number
- Net margin
- n/m
- not a meaningful number
- Free cash flow yield
- −28.9%
Cingulate's trailing earnings are negative, so it has no PE.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| R&D | $3.9M+85% | $5M+158% | $1.8M−15% | $1.9M−58% | $1.4M−64% | $4.3M−13% | $2.2M+23% | $2.7M+44% | $2.8M+99% | $2M−54% | $2.2M−2% | $1.5M−45% |
| SG&A | $1.8M−1% | $1.8M−29% | $1.1M−34% | $1.3M−31% | $1.9M+2% | $1.9M+4% | $1.5M+30% | $1.9M+47% | $3.1M+70% | $3.6M+91% | $5.7M+287% | $3.9M+102% |
| −$5.7M+45% | −$6.8M+52% | −$2.9M−23% | −$3.2M−50% | −$3.3M−43% | −$6.2M−9% | −$3.7M+26% | −$4.6M+45% | −$6M+83% | −$5.6M−10% | −$7.9M+114% | −$5.4M+17% | |
| Interest expense | $237.5K+127% | $112.5K−40% | $31.3K−83% | n/a | n/a | n/a | $209.7K+571% | $213.7K | n/a | n/a | $348.3K+66% | $236.4K+11% |
| Pre-tax income | −$6M+49% | −$6.9M+51% | −$3M−26% | −$3.2M−52% | −$4.1M−31% | −$6.2M−10% | −$3.9M+30% | −$5M+55% | −$7.3M+78% | −$6.3M+1% | −$9.3M+142% | −$5.9M+18% |
| Net income | −$6M+49% | −$6.9M+51% | −$3M−26% | −$3.2M−52% | −$4.1M−31% | −$6.2M−10% | −$3.9M+30% | −$5M+55% | −$7.3M+78% | −$6.3M+1% | −$9.3M+142% | −$5.9M+18% |
| −$72.60−16% | −$56.55−38% | −$7.21−92% | −$5.47−19% | −$2.34−97% | −$1.90−97% | −$1.06−85% | −$1.14−79% | −$1.35−42% | −$0.93−51% | −$0.95−10% | −$0.45−61% | |
| 82.4K+75% | 122.6K+144% | 412.1K+775% | 586.3K−40% | 1.8M+2045% | 3.3M+2573% | 3.6M+785% | 4.4M+649% | 5.4M+208% | 6.7M+105% | 9.8M+168% | 13.2M+200% |
EPS, diluted: 4 periods, Q4 FY22 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: Q4 FY22: share-days: the 12-month average over 365 days less the 9-month over 273, the two on one basis (x18.78). 3 periods, Q4 FY23 to Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Drug Manufacturers - General nearest Cingulate's size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| CINGCingulate | $72.4M | n/m | n/a | n/m | n/m | n/m | |
| LFVNLifevantage | $73.4M | 14.7× | 19.6× | 0.4× | −20% | 2.8% | |
| SPROSpero Therapeutics | $64.6M | 10.1× | 9.5× | 1.4× | −3% | 15.7% | |
| ATNMActinium Pharmaceuticals | $47.8M | 4.2× | 3.1× | n/m | n/m | n/m | |
| NATRNatures Sunshine Products | $213.8M | 12.0× | 20.6× | 0.4× | +7% | 3.7% | |
| ARVNArvinas | $477.3M | 45.6× | 52.3× | 1.5× | −15% | 2.9% | |
| PBYIPuma Biotechnology | $568.9M | 21.2× | 12.3× | 2.5× | −3% | 11.6% | |
| IRWDIronwood Pharmaceuticals | $571.7M | 4.5× | 14.9× | 1.5× | +26% | 33.4% | |
| ZVRAZevra Therapeutics | $582.6M | 10.5× | 12.3× | 4.3× | +119% | 42.8% | |
| CRMDCorMedix | $611.9M | 3.7× | 4.0× | 1.3× | +281% | 40.5% | |
| Peer median | $477.3M | 10.5× | 12.3× | 1.4× | +2% | 13.6% |
More on Cingulate
Each number over time
Its groups
About
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .